Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Crosses Below 50 Day Moving Average – Time to Sell?

Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.61 and traded as low as $0.5129. Galmed Pharmaceuticals shares last traded at $0.5701, with a volume of 35,225 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Galmed Pharmaceuticals currently has an average rating of “Sell”.

Galmed Pharmaceuticals Stock Up 9.4%

The firm has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.93. The company has a market cap of $3.12 million, a PE ratio of -0.46 and a beta of 0.47.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Wednesday, April 1st. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $1.43.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned about 1.28% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.